CHCWM – Cancer & Hematology Centers of West Michigan

CPI-200CL01 (Coordination Pharmaceuticals)

A Phase I, First-in-Human study evaluating the safety. tolerability, and pharmacokinetics of CPI-200 via intravenous infusion in patients with Advanced Solid Tumors. Mechanism of Action: Core-shell Nanoparticle carrying CPI-200 (prodrug of Cisplatin and Paclitaxel).

Target Patient Population: All solid tumors

Study Design: Drug is given through IV every 21 days